Organigram Global (OGI) Common Equity (2018 - 2026)

Organigram Global (OGI) posted quarterly Common Equity of $673.9 million for Q1 2026, up 1.97% on a QoQ basis from $660.9 million in Q4 2025.

Organigram Global (OGI) Common Equity (2018 - 2026) Analysis & Trends

Organigram Global (OGI) has reported Common Equity for 6 consecutive years, with $673.9 million the latest figure, recorded in Q1 2026.

Quarterly Common Equity changed N/A year-over-year to $673.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $673.9 million (changed N/A YoY) and the FY2025 annual result came in at $660.9 million, changed N/A from the prior year.
Common Equity rose to $673.9 million in Q1 2026 per OGI's latest filing, from $660.9 million in the prior quarter.
Over the last five years, Common Equity for OGI reached as high as $673.9 million in Q1 2026 and fell as low as $660.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Common Equity (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	21.93 Bn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	8.23 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	3.23 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	47.38 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	5.90 Bn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	56.13 Bn
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	14.66 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	3.41 Bn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	6.50 Bn
10	Organigram Global	89.89 Mn	122.96 Mn	28.97 Mn	673.92 Mn

Download Data